Synthroid market share "holding steady"
Executive Summary
Synthroid "monthly market share continues to hold steady and market growth remains healthy in the high single digits," Abbott VP-Investor Relations & Public Affairs Catherine Babington said. Third quarter sales were $216 mil., up from $166 mil. in the previous quarter. The levothyroxine product "reported unusually strong third-quarter sales due in part to trade and patient stocking." FDA is requiring Abbott to phase-down its distribution of Synthroid while the NDA, submitted Aug. 1, is pending at the agency (1"The Pink Sheet" July 16, p. 16)
You may also be interested in...
FDA Seeks To Cut Abbott Synthroid Distribution To 60% By August 2002
An FDA guidance on levothyroxine products calls for Abbott to reduce Synthroid distribution to 60% of current levels by August 2002, about the time the company anticipates FDA approval for the drug.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials